Valuation : Arcturus Therapeutics Holdings Inc.

Market Cap 450M 386M 362M 331M 623M 42.98B 626M 4.28B 1.67B 21.5B 1.69B 1.65B 71.71B P/E 2026 *
-4.8x
P/E 2027 * -4.24x
Enterprise Value 290M 249M 233M 214M 402M 27.73B 404M 2.76B 1.08B 13.87B 1.09B 1.07B 46.26B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 15.2x
Free-Float
92.01%
Yield 2026 *
-
Yield 2027 * -
1 day+2.15%
1 week+57.30%
Current month+180.73%
1 month+192.41%
3 months+124.27%
6 months+94.35%
Current year+163.78%
1 week 11.11
Extreme 11.11
16.59
1 month 5.57
Extreme 5.57
16.59
Current year 5.5
Extreme 5.5
16.59
1 year 5.5
Extreme 5.5
24.17
3 years 5.5
Extreme 5.5
45
5 years 5.5
Extreme 5.5
58.45
10 years 4.11
Extreme 4.11
129.71
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-28
Director of Finance/CFO 71 2026-04-30
Chief Tech/Sci/R&D Officer 65 -
Director TitleAgeSince
Chairman 83 2018-05-26
Director/Board Member 67 2018-05-26
Director/Board Member 67 2018-05-26
Date Insider Type Main position Quantity % Market Cap.
12/17/25 Free

Controller/Auditor

10,000 0.0368%
12/17/25 Free

General Counsel

54,000 0.1989%
12/17/25 Free

Chief Executive Officer

175,000 0.6445%
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+57.30%-7.81%-48.54% 450M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+3.40%+51.59%+93.39% 65.4B
-1.03%-1.52%+6.31%-5.28% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-2.41%-7.09%-8.16%+455.82% 27.16B
+0.37%+0.70%+37.37%-15.78% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.50%+1.60%+44.13%+151.30% 13.9B
Average +0.33%+6.44%+51.67%+168.91% 28.88B
Weighted average by Cap. +0.75%+0.80%+55.85%+154.78%

Financials

2026 *2027 *
Net sales 18.64M 16M 14.99M 13.72M 25.82M 1.78B 25.92M 177M 69.25M 891M 69.98M 68.46M 2.97B 29.58M 25.39M 23.78M 21.77M 40.98M 2.83B 41.13M 281M 110M 1.41B 111M 109M 4.72B
Net income -93.59M -80.31M -75.24M -68.87M -130M -8.94B -130M -890M -348M -4.47B -351M -344M -14.92B -114M -97.71M -91.53M -83.78M -158M -10.88B -158M -1.08B -423M -5.44B -427M -418M -18.15B
Net Debt -160M -137M -128M -118M -221M -15.26B -222M -1.52B -593M -7.63B -600M -587M -25.45B -
Logo Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Employees
109
Date Price Change Volume
26-08-27 US$16.17 +2.15% 1,127,283
26-08-26 US$15.83 +2.53% 2,230,326
26-08-25 US$15.44 +7.67% 2,212,078
26-08-24 US$14.34 +6.62% 2,412,776
26-08-21 US$13.45 +22.38% 2,856,256
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
15.83USD
Average target price
20.20USD
Spread / Average Target
+27.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARCT Stock